Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...
CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic ...
Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...
Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...
CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...
The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based ...
Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL We retrospectively analyzed 473 adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results